Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,558
datasets available to search
ShareScore release 0.9.0
Dataset results
1,558 results for “Chronic Kidney Disease”
Identification of mechanistic chronic kidney disease biomarkers by comprehensive bulk RNA-seq transcriptomics and SWATH proteomics of the rat sub-total nephrectomy model of kidney fibrosis [RNA-Seq_2]
GEO Series GSE253008. Rattus norvegicus. 6 samples. Type: Expression profiling by high throughput sequencing.
Kidney-targeted renalase agonist prevents cisplatin-induced chronic kidney disease by inhibiting regulated necrosis and inflammation
GEO Series GSE174014. Mus musculus. 6 samples. Type: Expression profiling by high throughput sequencing.
Renal singel-nuclear transcriptomics identifies novel therapeutic tragets in a preclinical model of chronic kidney disease.
GEO Series GSE291876. Sus scrofa. 6 samples. Type: Expression profiling by high throughput sequencing.
Identifying urinary RNA as non-invasive biomarkers for progression of chronic kidney disease
GEO Series GSE121978. Homo sapiens. 80 samples. Type: Non-coding RNA profiling by high throughput sequencing.
Data from: Prognosis of chronic kidney disease with normal-range proteinuria: The CKD-ROUTE study
Background: Although lower estimated glomerular filtration rate (eGFR) and higher proteinuria are high risks for mortality and kidney outcomes, the prognosis of chronic kidney disease (CKD) in patients with normal-range proteinuria remains unclear. Methods: In this prospective cohort study, 1138 newly visiting stage G2-G5 CKD patients were stratified into normal-range and abnormal-range proteinuria groups. Study endpoints were CKD progression (>50% eGFR loss or initiation of dialysis), cardiovascular events, and all-cause death. Results: In total, 927 patients who were followed for >6 months were included in the analysis. The mean age was 67 years, and 70.2% were male. During a median follow-up of 35 months, CKD progression, cardiovascular events, and mortality were observed in 223, 110, and 55 patients, respectively. Patients with normal-range proteinuria had a significantly lower risk for CKD progression (hazard ratio, 0.20; 95% confidence interval, 0.10-0.38) than those with abnormal-proteinuria by multivariate Cox proportional hazard analysis. We also analyzed patients with normal-range proteinuria (n=351). Nephrosclerosis was the most frequent cause of CKD among all patients with normal-range proteinuria (59.7%). During a median follow-up of 36 months, CKD progression, cardiovascular events, and mortality were observed in 10, 28, and 18 patients, respectively. The Kaplan-Meyer analysis demonstrated that the risks of CKD progression and cardiovascular events were not significantly different among CKD stages, whereas the risk of death was significantly higher in patients with advanced-stage CKD. Multivariate Cox proportional hazard analysis showed that the risk of three endpoints did not significantly differ among CKD stages. Conclusion: Newly visiting CKD patients with normal-range proteinuria, who tend to be overlooked during health checkups did not exhibit a decrease in kidney function even in advanced CKD stages under specialized nephrology care.
DIAGNOSTIC METHODS FOR CHRONIC KIDNEY DISEASE: A COMPREHENSIVE REVIEW
Open the record for dataset details and reuse information.
PATHOGENESIS OF CHRONIC KIDNEY DISEASE (CKD)
Open the record for dataset details and reuse information.
A Phase 3 Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Peritoneal Dialysis
ClinicalTrials.gov study NCT01017276. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Chronic Kidney Disease and Heart Failure With Preserved Ejection Fraction: The Role of Mitochondrial Dysfunction
ClinicalTrials.gov study NCT03960073. IPD Sharing: NO. Countries: 1. Publications: 0.
An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Patients With Chronic Kidney Disease in Pre-Dialysis or Dialysis
ClinicalTrials.gov study NCT01309295. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants With Established Atherosclerotic Cardiovascular and Chronic Kidney Disease.
ClinicalTrials.gov study NCT06675175. IPD Sharing: YES. Countries: 4. Publications: 0.
Is There a Digital Divide in Chronic Kidney Disease (CKD)?
ClinicalTrials.gov study NCT03067779. IPD Sharing: NO. Countries: 1. Publications: 0.
Prognostic Markers of Acute Heart Failure With Chronic Kidney Disease
ClinicalTrials.gov study NCT06006819. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Effects of Brazil Nut Supplementation in Patients With Chronic Kidney Disease Undergoing Conservative Treatment
ClinicalTrials.gov study NCT06394544. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Vitamin D Deficiency in Chronic Kidney Disease (CKD) Patients
ClinicalTrials.gov study NCT00958451. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Reliability of Muscle Strength and Activation Assessment Tools and Effects of an Online Therapeutic Exercise Program in Patients With Chronic Kidney Disease
ClinicalTrials.gov study NCT07292311. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Epidemiological Study of Fabry Disease Screening in Chronic Kidney Disease Patients
ClinicalTrials.gov study NCT05056636. IPD Sharing: Not stated. Countries: 1. Publications: 0.
The Effect and Mechanism of Xiqing Regulating Intestinal Homeostasis on Drug Efficacy of Chronic Kidney Disease
ClinicalTrials.gov study NCT07182942. IPD Sharing: Not stated. Countries: 1. Publications: 0.
The Effect of COVID-19 Pandemia on Follow up of Patients With Chronic Kidney Disease
ClinicalTrials.gov study NCT04874753. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Sleep Disturbances as a Non-Traditional Risk Factor in Chronic Kidney Disease- University of Illinois
ClinicalTrials.gov study NCT00817492. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.